Tesamorelin
Egrifta (FDA-approved brand)
Mechanism of Action
Stabilized GHRH analog that stimulates pituitary GH release with high potency and selectivity.
Key Benefits
- FDA-approved for HIV-associated lipodystrophy
- Significantly reduces visceral adipose tissue
- Improves lipid profiles and body composition
- Cognition improvement data in older adults
Dosing Protocol
FDA-approved for HIV lipodystrophy. Patient-specific 503A compounding permitted.
Ideal Candidates
HIV lipodystrophy (approved), visceral fat reduction, GH optimization.
Side Effects & Safety
Fluid retention, arthralgia, peripheral edema, injection site reactions.
Regulatory Status
FDA-ApprovedFDA-approved (Egrifta). Patient-specific 503A compounding permitted.
Frequently asked
What is Tesamorelin?+
Tesamorelin (Egrifta (FDA-approved brand)) is a peptide studied for visceral fat reduction and fda-approved. Stabilized GHRH analog that stimulates pituitary GH release with high potency and selectivity.
What is the dosing protocol for Tesamorelin?+
Literature commonly references 1 mg/day (low) to 2 mg/day (maintenance) via SubQ daily, on a 16–24 weeks cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of Tesamorelin?+
FDA-approved (Egrifta). Patient-specific 503A compounding permitted.
Where can I access Tesamorelin?+
Research-grade Tesamorelin is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.